Related Experiment Video
Updated: Nov 26, 2025
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.3K
A simple HPLC assay for determining eltrombopag concentration in human serum
Naoya Yanagimachi1, Naoshi Obara2, Mamiko Sakata-Yanagimoto2
1Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.
Biomedical Chromatography : BMC
|December 14, 2020
Summary
A new HPLC assay accurately measures eltrombopag levels in idiopathic thrombocytopenic purpura (ITP) patients. This method supports therapeutic drug monitoring for effective ITP treatment.
Area of Science:
- Pharmacology
- Analytical Chemistry
- Hematology
Background:
- Eltrombopag is a thrombopoietin receptor agonist used for idiopathic thrombocytopenic purpura (ITP) and aplastic anemia.
- Accurate measurement of eltrombopag serum concentration is crucial for therapeutic drug monitoring in ITP patients.
Purpose of the Study:
- To develop and validate a high-performance liquid chromatography (HPLC) assay for determining serum eltrombopag concentrations.
- To assess the assay's suitability for therapeutic drug monitoring in ITP.
Main Methods:
- Serum samples were prepared by protein precipitation with acetonitrile.
- Eltrombopag and diclofenac (internal standard) were separated using an octadecylsilyl silica-gel column.
- Detection was performed at 265 nm using a specific mobile phase.
Main Results:
- The calibration curve was linear within the 0.15-12.5 μg/mL range (r=0.9987).
- Recoveries exceeded 95.9% with coefficients of variation (CVs) below 2.8%.
- Intra-day and inter-day CVs ranged from 1.9-11.8% and 1.0-11.8%, respectively.
Conclusions:
- The developed HPLC assay is accurate and precise for quantifying serum eltrombopag.
- This method is suitable for therapeutic drug monitoring of eltrombopag in patients with ITP.
